Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/5991
|
| Title: | BPR1K653, a novel aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells |
| Authors: | Cheung, CH;Lin, WH;Hsu, TA;Hour, TC;Yeh, TK;Ko, S;Lien, TW;Coumar, MS;Liu, JF;Lai, WY;Shiao, HY;Lee, TR;Hsieh, HP;Chang, JY |
| Contributors: | National Institute of Cancer Research;Institute of Biotechnology and Pharmaceutical Research |
| Abstract: | Background: Over-expression of Aurora kinases promotes the tumorigenesis of cells. The aim of this study was to determine the preclinical profile of a novel pan-Aurora kinase inhibitor, BPR1K653, as a candidate for anti-cancer therapy. Since expression of the drug efflux pump, MDR1, reduces the effectiveness of various chemotherapeutic compounds in human cancers, this study also aimed to determine whether the potency of BPR1K653 could be affected by the expression of MDR1 in cancer cells. Principal Findings: BPR1K653 specifically inhibited the activity of Aurora-A and Aurora-B kinase at low nano-molar concentrations in vitro. Anti-proliferative activity of BPR1K653 was evaluated in various human cancer cell lines. Results of the clonogenic assay showed that BPR1K653 was potent in targeting a variety of cancer cell lines regardless of the tissue origin, p53 status, or expression of MDR1. At the cellular level, BPR1K653 induced endo-replication and subsequent apoptosis in both MDR1-negative and MDR1-positive cancer cells. Importantly, it showed potent activity against the growth of xenograft tumors of the human cervical carcinoma KB and KB-derived MDR1-positive KB-VIN10 cells in nude mice. Finally, BPR1K653 also exhibited favorable pharmacokinetic properties in rats. Conclusions and Significance: BPR1K653 is a novel potent anti-cancer compound, and its potency is not affected by the expression of the multiple drug resistant protein, MDR1, in cancer cells. Therefore, BPR1K653 is a promising anti-cancer compound that has potential for the management of various malignancies, particularly for patients with MDR1-related drug resistance after prolonged chemotherapeutic treatments. |
| Date: | 2011-08 |
| Relation: | PLoS ONE. 2011 Aug;6(8):Article number e23485. |
| Link to: | http://dx.doi.org/10.1371/journal.pone.0023485 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1932-6203&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000295832000020 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=80052005083 |
| Appears in Collections: | [張俊彥] 期刊論文
[謝興邦] 期刊論文
[葉燈光] 期刊論文
[徐祖安] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| SCP80052005083.pdf | | 3262Kb | Adobe PDF | 557 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
